Background: Several guidelines exist on the appropriate use of serum tumour markers in the
management of patients with cancer. This study audited tumour marker requesting against …

The role of biomarkers in drug discovery and development has gained precedence over the
years. As biomarkers become integrated into drug development and clinical trials, quality …

Protein biomarkers are used for various purposes in drug development and clinical
diagnosis and prognosis. In this review, a fit-for-purpose method validation approach is …

Context.—Inferences from tumor marker studies are complicated by a variety of statistical
concerns, which can make proper interpretation of results difficult. This article focuses on …

Most of the presently available cancer markers are neither specific for malignancy nor allow
early diagnosis. However, the recent elucidation of the molecular events occurring during …

Context.—The authors announce the launch of the Consortium for Analytic Standardization
in Immunohistochemistry, funded with a grant from the National Cancer Institute. As with …

Context Laboratories must validate all assays before they can be used to test patient
specimens, but currently there are no evidence-based guidelines regarding validation of …

Only a few markers have been instrumental in the diagnosis of cancer. In contrast, tumor
markers play a critical role in the monitoring of patients. The patient's clinical status and …

Background: Plasma tumor biomarkers are widely used clinically for monitoring response to
therapy and detecting cancer recurrence. Only a limited number of them, however, have …

Clinical proteomics has the potential to enable the early detection of cancer through the
development of multiplex assays that can inform clinical decisions. However, there has been …